May 9, 2019
Takeda Pharmaceutical said on May 9 that it has agreed to sell its dry eye treatment Xiidra (lifitegrast) to Swiss giant Novartis for US$5.3 billion as part of its efforts to pay down debts it incurred from the £46 billion...read more